GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » EV-to-EBITDA

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) EV-to-EBITDA : 67.97 (As of May. 04, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shenzhenlubris Pharmaceuticals Co's enterprise value is ¥43,928 Mil. Shenzhenlubris Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was ¥646 Mil. Therefore, Shenzhenlubris Pharmaceuticals Co's EV-to-EBITDA for today is 67.97.

The historical rank and industry rank for Shenzhenlubris Pharmaceuticals Co's EV-to-EBITDA or its related term are showing as below:

SZSE:002294' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.94   Med: 29.58   Max: 500.13
Current: 67.69

During the past 13 years, the highest EV-to-EBITDA of Shenzhenlubris Pharmaceuticals Co was 500.13. The lowest was 11.94. And the median was 29.58.

SZSE:002294's EV-to-EBITDA is ranked worse than
90.39% of 489 companies
in the Medical Devices & Instruments industry
Industry Median: 15.46 vs SZSE:002294: 67.69

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-04), Shenzhenlubris Pharmaceuticals Co's stock price is ¥40.90. Shenzhenlubris Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ¥0.540. Therefore, Shenzhenlubris Pharmaceuticals Co's PE Ratio (TTM) for today is 75.74.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Shenzhenlubris Pharmaceuticals Co EV-to-EBITDA Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co EV-to-EBITDA Chart

Shenzhenlubris Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 90.70 29.80 32.36 34.84 32.00

Shenzhenlubris Pharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.76 42.63 54.36 32.00 54.05

Competitive Comparison of Shenzhenlubris Pharmaceuticals Co's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Shenzhenlubris Pharmaceuticals Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhenlubris Pharmaceuticals Co's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's EV-to-EBITDA falls into.


;
;

Shenzhenlubris Pharmaceuticals Co EV-to-EBITDA Calculation

Shenzhenlubris Pharmaceuticals Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=43927.797/646.311
=67.97

Shenzhenlubris Pharmaceuticals Co's current Enterprise Value is ¥43,928 Mil.
Shenzhenlubris Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥646 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhenlubris Pharmaceuticals Co  (SZSE:002294) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Shenzhenlubris Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=40.90/0.540
=75.74

Shenzhenlubris Pharmaceuticals Co's share price for today is ¥40.90.
Shenzhenlubris Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.540.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Shenzhenlubris Pharmaceuticals Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhenlubris Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 6009 Shennan Road, 37th Floor, Main Building, Chegongmiao Lvjing Plaza, Futian District, Guangdong, Shenzhen, CHN, 518040
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
Executives
Yan Jie Directors, executives
Yang Jian Feng Secretary, Director
Zhao Song Ping Executives
Liu Jun Executives
Li Ai Zhen Supervisors
Chen Ping Executives
Ye Cheng Hai Director
Lu Feng Executives, directors
Chen Qiong Xing Supervisors
Li Ying Hui Supervisors
Pan Ling Man Independent director
Zhang Zhong Xing Executives

Shenzhenlubris Pharmaceuticals Co Headlines

No Headlines